Start here if you're new
what it is
Amneal makes generic, branded, and biosimilar medicines and sells them in North America, Asia, and Europe.
how it gets paid
Last year Amneal Pharma made $3.0B in revenue. Generics was the main engine at $1.44B, or 48% of sales.
why it's growing
Revenue grew 8.0% last year. The latest quarter showed a big vs. prior year revenue step-up — check the filing for comparable periods. EPS swung versus a very small prior-period base; do not treat headline “1000%” EPS growth as literal without verifying the denominator.
what just happened
Amneal posted $2.2B in revenue and $0.11 EPS, with gross margin still at 37.0%.
At a glance
B balance sheet — gets the job done, barely
20/100 earnings predictability — expect surprises
44.5x trailing p/e — you're paying up for this one
3.5% return on capital — nothing to write home about
-$0.18 fy2024 eps est
xvary composite: 46/100 — below average
What they do
Amneal makes generic, branded, and biosimilar medicines and sells them in North America, Asia, and Europe.
Amneal sells about 270 product families. That is 270 ways to be boring on purpose. If your pharmacy fills one of its products, leaving is painful because the medicine is already approved, made, and moving.
How they make money
$3.0B
annual revenue · their business grew +8.0% last year
Generics
$1.44B
+6.0%
Branded medicines
$0.69B
+8.0%
Sterile injectables
$0.39B
+12.0%
Biosimilars
$0.27B
+25.0%
Other dosage forms
$0.21B
+3.0%
The products that matter
generic and brand portfolio
generic & brand drugs
current engine · still doing the heavy lifting
This is the business paying the bills, but analysts still forecast a -$0.18 EPS result for 2024, so the base portfolio has not done enough yet.
cash base
biosimilar pipeline and launches
biosimilars
part of the Amneal 2.0 plan
This is part of the 2026 pitch. A stock up 69% in a year and trading at 44.5x earnings tells you investors expect contribution, not slideware.
2026 watch
branded parkinson's launch
crexont
new launch · phase 4 checkpoint
CREXONT is the cleanest single-product catalyst on this page. The next checkpoint is the Phase 4 ELEVATE-PD trial, and this setup needs progress, not patience theater.
phase 4 catalyst
Key numbers
$3.0B
annual revenue
That is the size of the whole business. It is also just a bit larger than the $2.7B debt load.
37.0%
gross margin
Gross margin means sales left after direct costs. At 37.0%, Amneal keeps 37 cents from each revenue dollar before overhead.
$2.7B
long-term debt
Debt is borrowed money. At $2.7B, it is the number that keeps your attention when rates stay high.
44.5x
trailing p/e
Price to earnings means what you pay for each dollar of profit. At 44.5x, you are paying up for low reported earnings.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 20 / 100
- long-term debt $2.7B (42% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for AMRX right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Amneal posted $2.2B in revenue and $0.11 EPS, with gross margin still at 37.0%.
Revenue jumped 181% vs. prior year (confirm the comparable quarter in the 10-Q). EPS improved off a thin prior comparison — verify filing math instead of feed-style triple-digit EPS labels. Gross margin stayed at 37.0%, which tells you the product mix did the heavy lifting.
$2.2B
revenue
$0.11
eps
37.0%
gross margin
revenue jump
The $2.2B revenue print mattered most because it shows the business can grow fast even with heavy debt.
source: company earnings report
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk is turnaround execution under leverage. AMRX is not fighting abstract macro noise. It is trying to prove that newer products can carry a stock already priced for improvement while $2.7B of debt stays on the books.
med
CREXONT and biosimilars fail to convert the story into earnings.
A 44.5x multiple leaves little room for another stretch where analysts still expect losses. The market already moved first.
If losses linger past the current -$0.18 2024 forecast setup, the rerating starts to look like hope priced as fact.
med
$2.7B of long-term debt makes delays more expensive.
Debt at 42% of capital is manageable when launches work. It is less comfortable when execution drags or earnings stay thin.
This does not have to become a balance-sheet crisis to hurt you. It only has to reduce the margin for error while the market is paying a premium multiple.
med
Pending legal cases stay noisy for longer.
February 2025 and March 2024 filings flagged the issue. We do not have quantified exposure here, and that uncertainty is the point.
Litigation can pressure cash, management attention, or both. When the rest of the thesis already asks for execution, extra noise matters.
If pricing slips 1% on $3.0B of sales, you lose $30M. That is the whole game here.
source: institutional data · regulatory filings · risk analysis
Pay attention to
what validates it
The earnings path has to improve from the current -$0.18 2024 forecast.
That is the cleanest scoreboard on the page. If earnings do not improve, the stock is asking you to trust a 44.5x multiple on faith.
next checkpoint
The next quarterly report and any ELEVATE-PD update.
This is where you want proof beats: trial progress, product traction, and any change in the earnings path. This stock does not need more adjectives. It needs cleaner numbers.
chart vs. business
See whether 69% momentum survives a 20 / 100 stability profile.
Low stability means the market can rerate this fast in both directions. If updates disappoint, the stock has already shown you it does not trade with much cushioning.
what weakens it
Debt staying near $2.7B while litigation stays unresolved.
One issue on its own is manageable. Both together make the turnaround harder to underwrite and easier to doubt.
Analyst rankings
earnings predictability
20 / 100
low visibility. expect surprises, not a straight line.
barchart opinion
100% buy
in human-speak, sentiment is fully supportive. that tells you how people feel, not what the next income statement says.
xvary composite
46 / 100
below average overall. momentum looks better than quality and stability.
risk rank
3
middle of the pack. safer than 50% of stocks, but not the kind you forget to check.
source: institutional data
Institutional activity
institutional ownership data for AMRX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$12
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive